Reciprocal regulation of eNOS, H2S and CO-synthesizing enzymes in human atheroma: Correlation with plaque stability and effects of simvastatin

Redox Biology

Volumn 12, Issue , 2017, Pages 70-81

  Sigala, Fragiska ^a   Efentakis, Panagiotis ^a   Karageorgiadi, Dimitra ^a   Filis, Konstadinos ^a   Zampas, Paraskevas ^a   Iliodromitis, Efstathios K ^b   Zografos, George ^a   Papapetropoulos, Andreas ^a   Andreadou, Ioanna ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Carotid plaques; Heme oxygenase 1; Hydrogen sulfide; Nitric oxide; Nitro oxidative stress

Indexed keywords

3 NITROTYROSINE; CYSTATHIONINE BETA SYNTHASE; CYSTATHIONINE GAMMA LYASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANYLATE CYCLASE; HEME OXYGENASE 1; HYDROGEN SULFIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MALONALDEHYDE; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SIMVASTATIN; SOLUBLE GUANYLATE CYCLASE ALPHA1; SOLUBLE GUANYLATE CYCLASE BETA1; UNCLASSIFIED DRUG; HIF1A PROTEIN, HUMAN; HMOX1 PROTEIN, HUMAN; INDUCIBLE NITRIC OXIDE SYNTHASE; NOS2 PROTEIN, HUMAN; NOS3 PROTEIN, HUMAN; NOX4 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INTERNAL CAROTID ARTERY OCCLUSION; MAJOR CLINICAL STUDY; MALE; NITROSATIVE STRESS; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY OBSTRUCTION; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; PROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CAROTID STENOSIS; CYSTATHIONINE BETA-SYNTHASE; CYSTATHIONINE GAMMA-LYASE; FEMALE; HEME OXYGENASE-1; HUMANS; HYDROGEN SULFIDE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MIDDLE AGED; NADPH OXIDASE 4; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PLAQUE, ATHEROSCLEROTIC; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-AKT; SIMVASTATIN;

EID: 85012977500     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2017.02.006     Document Type: Article

References (69)

1. [1] Den Hartog, A.G., Achterberg, S., Molletal, F.L., Asymptomatic carotid artery stenosis and the risk of ischemic stroke according to subtype in patients with clinical manifest arterial disease. Stroke 44 (2013), 1002–1007.
2. [2] Inzitari, D., Eliasziw, M., Gates, P., Sharpe, B.L., Chan, R.K., Meldrum, H.E., Barnett, H.J., The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American symptomatic Carotid Endarterectomy trial Collaborators. New Engl. J. Med 342 (2000), 1693–1700.
3. [3] Petty, G.W. Jr, Brown, R.D., Whisnant, J.P., Sicks, J.D., O'Fallon, W.M., Wiebers, D.O., Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 30 (1999), 2513–2516.
4. [4] Bentzon, J.F., Otsuka, F., Virmani, R., Falk, E., Mechanisms of plaque formation and rupture. Circ. Res. 114 (2014), 1852–1866.
5. [5] Hopkins, P.N., Molecular biology of atherosclerosis. Physiol. Rev. 93 (2013), 1317–1542.
6. [6] Andreadou, I., Iliodromitis, E.K., Rassaf, T., Schulz, R., Papapetropoulos, A., Ferdinandy, P., The role of gasotransmitters NO, H2S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning. Br. J. Pharm. 172 (2015), 1587–1606.
7. [7] Szabo, C., Gasotransmitters in cancer: from pathophysiology to experimental therapy. Nat. Rev. Drug Disco. 15 (2016), 185–203.
8. [8] Kabil, O., Banerjee, R., Enzymology of H(2)S biogenesis, decay and signaling. Antiox. Redox Signal 20 (2014), 770–782.
9. [9] Kimura, H., Production and physiological effects of hydrogen sulfide. Antiox. Redox Signal 20 (2014), 783–793.
10. 2S bioavailability in endothelial dysfunction. Trends Pharmacol. Sci. 36 (2015), 568–578.
11. [11] Kockx, M.M., Herman, A.G., Apoptosis in atherosclerosis: beneficial or detrimental?. Cardiovasc. Res 45 (2000), 736–746.
12. [12] Mihaylova, B., Emberson, J., Blackwell, L., Keech, A., Simes, J., Barnes, E.H., Voysey, M., Gray, A., Collins, R., Baigent, C., The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380 (2012), 581–590.
13. [13] Ludman, A., Venugopal, V., Yellon, D.M., Hausenloy, D.J., Statins and cardioprotection—more than just lipid lowering?. Pharmacol. Ther. 122 (2009), 30–43.
14. [14] Lahera, V., Goicoechea, M., de Vinuesa, S.G., Miana, M., de las Heras, N., Cachofeiro, V., Luno, J., Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr. Med. Chem. 14 (2007), 243–248.
15. [15] North American Symptomatic Carotid Endarterectomy Trial Collaborators, Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N. Engl. J. Med. 325 (1991), 445–453.
16. [16] Stary, H.C., Chandler, A.B., Dinsmore, R.E., Fuster, V., Glagov, S., Insull, W. Jr., Rosenfeld, M.E., Schwartz, C.J., Wagner, W.D., Wissler, R.W., A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on vascular Lesions of the Council on Arteriosclerosis. Am. Heart Assoc. Circ. 92 (1995), 1355–1374.
17. [17] Papalambros, E., Sigala, F., Georgopoulos, S., Panou, N., Kavantzas, N., Agapitos, M., Bastounis, E., Vascular endothelial growth factor and matrix Metalloproteinase-9 expression in human carotid atherosclerotic plaques: relationship with plaque destabilization via neovascularization. Cerebrovasc. Dis. 18 (2004), 160–165.
18. 2S engages a cGMP-dependent protein kinase G/phospholamban pathway. Cardiovasc. Res 106 (2015), 432–442.
19. [19] Sigala, F., Kotsinas, A., Savari, P., Filis, K., Markantonis, S., Iliodromitis, E.K., Gorgoulis, V.G., Andreadou, I., Oxidized LDL in human carotid plaques is related to symptomatic carotid disease and lesion instability. J. Vasc. Surg. 52 (2010), 704–713.
20. [20] Liu, D., Lei, L., Desir, M., Huang, Y., Cleman, J., Jiang, W., Fernandez-Hernando, C., Di Lorenzo, A., Sessa, W.C., Giordano, F.J., Smooth muscle hypoxia-inducible factor 1α links intravascular pressure and atherosclerosis—Brief Report. Arterioscler. Thromb. Vasc. Biol. 36 (2016), 442–445.
21. [21] Akhtar, S., Hartmann, P., Karshovska, E., Rinderknecht, F.A., Subramanian, P., Gremse, F., Grommes, J., Jacobs, M., Kiessling, F., Weber, C., Steffens, S., Schober, A., Endothelial hypoxia-inducible factor-1α promotes atherosclerosis and monocyte recruitment by upregulating MicroRNA-19a. Hypertension 66 (2015), 1220–1226.
22. [22] Tawakol, A., Singh, P., Mojena, M., Pimentel-Santillana, M., Emami, H., MacNabb, M., Rudd, J.H., Narula, J., Enriquez, J.A., Través, P.G., Fernández-Velasco, M., Bartrons, R., Martín-Sanz, P., Fayad, Z.A., Tejedor, A., Boscá, L., HIF-1α and PFKFB3 mediate a tight Relationship Between proinflammatory activation and anaerobic metabolism in atherosclerotic macrophages. Arterioscler. Thromb. Vasc. Biol. 35 (2015), 1463–1471.
23. [23] Zhao, R., Feng, J., He, G., Hypoxia increases Nrf2-induced HO-1 expression via the PI3K/Akt pathway. Front. Biosci. (Landmark Ed.) 21 (2016), 385–396.
24. 4 is a new target gene of the hypoxia-inducible factor-1. Mol. Biol. Cell 21 (2010), 2087–2096.
25. [25] Idelman, G., Smith, D.L., Zucker, S.D., Bilirubin inhibits the up-regulation of inducible nitric oxide synthase by scavenging reactive oxygen species generated by the toll-like receptor 4-dependent activation of NADPH oxidase. Redox Biol. 5 (2015), 398–408.
26. [26] Szocs, K., Lassegue, B., Sorescu, D., Hilenski, L.L., Valppu, L., Couse, T.L., Wilcox, J.N., Quinn, M.T., Lambeth, J.D., Griendling, K.K., Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler. Thromb. Vasc. Biol. 22 (2002), 21–27.
27. [27] Bedard, K., Krause, K.-H., The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 87 (2007), 245–313.
28. [28] Li, T., Tian, H., Zhao, Y., An, F., Zhang, L., Zhang, J., Peng, J., Zhang, Y., Guo, Y., Heme oxygenase-1 inhibits progression and destabilization of vulnerable plaques in a rabbit model of atherosclerosis. Eur. J. Pharm. 672 (2011), 143–152.
29. [29] Espinola-Klein, C., Blankenberg, S., Münzel, T., Is heme oxygenase-1 a causal player for plaque stability?. Stroke, 36, 2005 (1901-193).
30. [30] Yet, S.-F., Layne, M.D., Liu, X., Chen, Y.-H., Ith, B., Sibinga, E.S., Perrella, M.A., Absence of heme oxygenase-1 exacerbates atherosclerotic lesion formation and vascular remodeling. FASEB J. 17 (2003), 1759–1761.
31. [31] Huang, H., Koelle, P., Fendler, M., Schröttle, A., Czihal, M., Hoffmann, U., Conrad, M., Kuhlencordt, P.J., Induction of inducible nitric oxide synthase (iNOS) expression by oxLDL inhibits macrophage derived foam cell migration. Atherosclerosis 235 (2014), 213–222.
32. [32] Badimon, L., Vilahur, G., Thrombosis formation on atherosclerotic lesions and plaque rupture. J. Int. Med. 276 (2014), 618–632.
33. [33] Fulton, D., Gratton, J.P., McCabe, T.J., Fontana, J., Fujio, Y., Walsh, K., Franke, T.F., Papapetropoulos, A., Sessa, W.C., Regulation of endothelium derived nitric oxide production by the protein kinase Akt. Nature 399 (1999), 597–601.
34. [34] Fernández-Hernando, C., József, L., Jenkins, D., Di Lorenzo, A., Sessa, W.C., Absence of Akt1 reduces vascular smooth muscle cell migration and survival and induces features of plaque vulnerability and cardiac dysfunction during atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29 (2009), 2033–2040.
35. [35] Francois, M., Kojda, G., Effect of hypercholesterolemia and of oxidative stress on the nitric oxide-cGMP pathway. Neurochem. Int 45 (2004), 955–961.
36. [36] Katsouda, A., Bibli, S.-I., Pyriochou, A., Szabo, C., Papapetropoulos, A., Regulation and role of endogenously produced hydrogen sulfide in angiogenesis. Pharmacol. Res 113 (2016), 175–185.
37. [37] Nakayama, T., Kurobe, H., Sugasawa, N., Kinoshita, H., Higashida, M., Matsuoka, Y., Yoshida, Y., Hirata, Y., Sakata, M., Maxfield, M.W., Shimabukuro, M., Takahama, Y., Sata, M., Tamaki, T., Kitagawa, T., Tomita, S., Role of macrophage-derived hypoxia-inducible factor (HIF)−1α as a mediator of vascular remodelling. Cardiovasc. Res. 99 (2013), 705–715.
38. [38] Pedruzzi, E., Guichard, C., Ollivier, V., Driss, F., Fay, M., Prunet, C., Marie, J.C., Pouzet, C., Samadi, M., Elbim, C., O'Dowd, Y., Bens, M., Vandewalle, A., Gougerot-Pocidalo, M.A., Lizard, G., Ogier-Denis, E., NAD(P)H oxidase Nox-4 mediates 7-ketocholesterol-induced endoplasmic reticulum stress and apoptosis in human aortic smooth muscle cells. Mol. Cell. Biol. 24 (2004), 10703–10717.
39. [39] Sorescu, D., Weiss, D., Lassegue, B., Clempus, R.E., Szocs, K., Sorescu, G.P., Valppu, L., Quinn, M.T., Lambeth, J.D., Vega, J.D., Taylor, W.R., Griendling, K.K., Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105 (2002), 1429–1435.
40. [40] Cheng, C., Noordeloos, A.M., Jeney, V., Soares, M.P., Moll, F., Pasterkamp, G., Serruys, P.W., Duckers, H.J., Heme oxygenase 1 determines atherosclerotic lesion progression into a vulnerable plaque. Circulation 119 (2009), 3017–3027.
41. [41] Siow, R.C., Sato, H., Mann, G.E., Heme oxygenase-carbon monoxide signalling pathway in atherosclerosis: anti-atherogenic actions of bilirubin and carbon monoxide?. Cardiovasc. Res 41 (1999), 385–394.
42. [42] Cau, S.B., Carneiro, F.S., Tostes, R.C., Differential modulation of nitric oxide synthases in aging: therapeutic opportunities. Fron. Physiol., 3, 2012, 218.
43. [43] Mani, S., Untereiner, A., Wu, L., Wang, R., Hydrogen sulfide and the pathogenesis of atherosclerosis. Antiox. Redox Sign 20 (2014), 805–817.
44. [44] Coletta, C., Papapetropoulos, A., Erdelyi, K., Olah, G., Modis, K., Panopoulos, P., Asimakopoulou, A., Gero, D., Sharina, I., Martin, E., Szabo, C., Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. Proc. Nat. Acad. Sci. USA 109 (2012), 9161–9166.
45. [45] Michel, J.B., Martin-Ventura, J.L., Nicoletti, A., Ho-Tin-Noe, B., Pathology of human plaque vulnerability: mechanisms and consequences of intraplaque haemorrhages. Atherosclerosis 234 (2014), 311–319.
46. [46] Mani, S., Li, H., Untereiner, A., Wu, L., Yang, G., Austin, R.C., Dickhout, J.G., Lhoták, Š., Meng, Q.H., Wang, R., Decreased endogenous production of hydrogen sulfide accelerates atherosclerosis. Circulation 127 (2013), 2523–2534.
47. [47] Suzuki, K., Olah, G., Modis, K., Coletta, C., Kulp, G., Gerö, D., Szoleczky, P., Chang, T., Zhou, Z., Wu, L., Wang, R., Papapetropoulos, A., Szabo, C., Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function. Proc. Natl. Acad. Sci. USA 108 (2011), 13829–13834.
48. [48] Carballal, S., Trujillo, M., Cuevasanta, E., Bartesaghi, S., Möller, M.N., Folkes, L.K., García-Bereguiaín, M.A., Gutiérrez-Merino, C., Wardman, P., Denicola, A., Radi, R., Alvarez, B., Reactivity of hydrogen sulfide with peroxynitrite and other oxidants of biological interest. Free Radic. Biol. Med. 50 (2011), 196–205.
49. 2 activation. Diabetes 65 (2016), 3171–3184.
50. [50] Stuart, S.A., Robertson, J.D., Marrion, N.V., Robinson, E.S., Chronic pravastatin but not atorvastatin treatment impairs cognitive function in two rodent models of learning and memory. PloS One, 8, 2013, e75467.
51. [51] Ceriello, A., Taboga, C., Tonutti, L., Quagliaro, L., Piconi, L., Bais, B., Da Ros, R., Motz, E., Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 106 (2002), 1211–1218.
52. [52] Shen, W., Shi, H.M., Fan, W.H., Luo, X.P., Jin, B., Li, Y., The effects of simvastatin on angiogenesis: studied by an original model of atherosclerosis and acute myocardial infarction in rabbit. Mol. Biol. Rep. 38 (2011), 3821–3828.
53. [53] Chen, S.M., Li, Y.G., Wang, D.M., Zhang, G.H., Tan, C.J., Expression of heme oxygenase-1, hypoxia inducible factor-1alpha, and ubiquitin in peripheral inflammatory cells from patients with coronary heart disease. Clin. Chem. Lab. Med 47 (2009), 327–333.
54. [54] Sarath, T.S., Waghe, P., Gupta, P., Choudhury, S., Kannan, K., Pillai, A.H., Harikumar, S.K., Mishra, S.K., Sarkar, S.N., Atorvastatin ameliorates arsenic-induced hypertension and enhancement of vascular redox signaling in rats. Toxicol. Appl. Pharm. 280 (2014), 443–454.
55. [55] Li, J., Wang, J.J., Yu, Q., Chen, K., Mahadev, K., Zhang, S.X., Inhibition of reactive oxygen species by Lovastatin downregulates vascular endothelial growth factor expression and ameliorates blood-retinal barrier breakdown in db/db mice: role of NADPH oxidase 4. Diabetes 59 (2010), 1528–1538.
56. [56] Nachtigal, P., Kopecky, M., Solichova, D., Zdansky, P., Semecky, V., The changes in the endothelial expression of cell adhesion molecules and iNOS in the vessel wall after the short-term administration of simvastatin in rabbit model of atherosclerosis. J. Pharm. Pharm. 57 (2005), 197–203.
57. [57] Mrad, M.F., Mouawad, C.A., Al-Hariri, M., Eid, A.A., Alam, J., Habib, A., Statins modulate transcriptional activity of heme-oxygenase-1 promoter in NIH 3T3 Cells. J. Cell. Biochem. 113 (2012), 3466–3475.
58. [58] Tu, Y.P., Chuang, S.J., Chen, S.C., Liu, Y.H., Chen, C.F.T.C., Simvastatin induces the expression of hemeoxygenase-1 against ischemia-reperfusion injury on the testes in rats. Toxicol. Lett. 207 (2011), 242–250.
59. [59] Balakumar, P., Kathuria, S., Taneja, G., Kalra, S., Mahadevan, N., Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?. J. Mol. Cell. Cardiol. 52 (2012), 83–92.
60. 2S generation via activating Akt signaling in macrophage. Pharmacol. Res 87 (2014), 18–25.
61. 2S formation in perivascular adipose tissue. Pharmacol. Res. 63 (2011), 68–76.
62. [62] van den Born, J.C., Mencke, R., Conroy, S., Zeebregts, C.J., van Goor, H., Hillebrands, J.L., Cystathionine γ-lyase is expressed in human atherosclerotic plaque microvessels and is involved in micro-angiogenesis. Sci. Rep., 6, 2016, 34608.
63. [63] Cuspidi, C., Negri, F., Giudici, V., Capra, A., Sala, C., Effects of antihypertensive drugs on carotid intima-media thickness: focus on angiotensin II receptor blockers. A review of randomized, controlled trials. Integr. Blood Press. Control 2 (2009), 1–8.
64. [64] Sattler, K.J., Woodrum, J.E., Galili, O., Olson, M., Samee, S., Meyer, F.B., Zhu, X.Y., Lerman, L.O., Lerman, A., Concurrent treatment with renin-angiotensin system blockers and acetylsalicylic acid reduces nuclear factor kappaB activation and C-reactive protein expression in human carotid artery plaques. Stroke 36 (2005), 14–20.
65. [65] Savoia, C., Schiffrin, E.L., Inhibition of the renin angiotensin system: implications for the endothelium. Curr. Diab. Rep. 6 (2006), 274–278.
66. [66] Bucci, M., Vellecco, V., Cantalupo, A., Brancaleone, V., Zhou, Z., Evangelista, S., Calderone, V., Papapetropoulos, A., Cirino, G., Hydrogen sulfide accounts for the peripheral vascular effects of zofenopril independently of ACE inhibition. Cardiovasc. Res 102 (2014), 138–147.
67. [67] Tian, S., Ge, X., Wu, K., Yang, H., Liu, Y., Ramipril protects the endothelium from high glucose-induced dysfunction through CaMKKβ/AMPK and heme oxygenase-1 activation. J. Pharmacol. Exp. Ther. 350 (2014), 5–13.
68. [68] Tsutsui, M., Shimokawa, H., Otsuji, Y., Yanagihara, N., Pathophysiological relevance of NO signaling in the cardiovascular system: novel insight from mice lacking all NO synthases. Pharm., Ther. 128 (2010), 499–508.
69. [69] Libby, P., Inflammation in atherosclerosis. Nature, 202, 2002, 420 868.